Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.70 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.70 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | ANPEP | P15144 | 1/20 | 0.61 |
| ▸ | DPP4 | P27487 | 2/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677967 | 1.00 | SLC1A3 (0.70) | SLC1A3SLC1A1DPP8DPP7HTT | |
| SCHEMBL2037306 | 1.00 | SLC1A3 (0.70) | SLC1A3SLC1A1DPP8DPP7HTT | |
| Hydrochloric Acid SCHEMBL5652476 | 0.99 | SLC1A3 (0.69) | SLC1A3SLC1A1DPP8DPP7HTT | |
| Hydrochloric Acid SCHEMBL29025567 | 0.99 | SLC1A3 (0.69) | SLC1A3SLC1A1DPP8DPP7HTT | |
| Hydrochloric Acid SCHEMBL6751263 | 0.99 | SLC1A3 (0.69) | SLC1A3SLC1A1DPP8DPP7HTT | |
| SCHEMBL453671 | 0.96 | DPP8 (0.69) | SLC1A3SLC1A1DPP8DPP7HTT | |
| SCHEMBL5816135 | 0.96 | DPP8 (0.69) | SLC1A3SLC1A1DPP8DPP7HTT | |
| SCHEMBL464672 | 0.96 | DPP8 (0.69) | SLC1A3SLC1A1DPP8DPP7HTT | |
| Hydrochloric Acid SCHEMBL18770783 | 0.95 | DPP8 (0.68) | SLC1A3SLC1A1DPP8DPP7HTT | |
| Hydrochloric Acid SCHEMBL7297967 | 0.95 | DPP8 (0.68) | SLC1A3SLC1A1DPP8DPP7HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | claimed |
| EP-3584277-B1 | ANTIMICROBIAL SILICONE RUBBER, PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU DOBIOM MEDICAL TECH CO LTD (CN) | 2022-06-29 | — | — | EP | claimed |
| US-6590061-B1 | Synthetic polypeptide or peptides having narrow molecular weight distribution used as telechelic polymers for synthesis of block or graft copolymers | INSTITUTE OF MACROMOLECULAR CHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-07-08 | — | — | US | claimed |
| EP-1088020-B1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE (CZ) | 2002-12-18 | — | — | EP | claimed |
| EP-1088020-A1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) | 2001-04-04 | — | — | EP | claimed |
| WO-1999064495-A1 | FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) | 1999-12-16 | — | — | WO | claimed |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MED LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4734770-A1 | COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-02-05 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| EP-4598592-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | Owlstone Medical Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025006362-A1 | COMPOUNDS THAT MODULATE GPRC6A RECEPTOR AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240325561-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | SEAGEN INC (US) | 2024-10-03 | — | — | US | disclosed |
| EP-0239362-B1 | ANTI-TUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-12-04 | — | — | EP | disclosed |
| EP-0446699-A1 | Inhibitors of nitric oxide biosynthesis | MERRELL PHARMACEUTICALS INC. (US) | 1991-09-18 | — | — | EP | disclosed |
| US-4999297-A | Culturing Animal Cells on a Polymethionine Surface | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0367514-A2 | Human leukocyte elastase inhibitors and methods for producing and using same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-05-09 | — | — | EP | disclosed |
| WO-1990004409-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS AND METHODS OF PRODUCING AND USING SAME | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1990-05-03 | — | — | WO | disclosed |
| EP-0239362-A2 | Anti-tumor agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-09-30 | — | — | EP | disclosed |
| US-4559340-A | DIURETICS; GLAUCOMA | SCHERING CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034237-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | CSGALNACT1, SLC43A1, OSTC | SLC1A3 46/4885SLC1A1 15/4885DPP8 1211/4885 |
| US-20260125418-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | BRCA1, L3MBTL1, LMNA | SLC1A3 3087/4885SLC1A1 2802/4885DPP8 2870/4885 |
| US-20240325561-A1 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS | EGFR, HDGF, CD47 | SLC1A3 1626/4885SLC1A1 1167/4885DPP8 2810/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | SLC1A3 3398/4885SLC1A1 3882/4885DPP8 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.